Condition (MeSH)
Diabetic Ketoacidosis
ClinicalTrials.gov lists 72 trials for Diabetic Ketoacidosis or a narrower condition beneath it. Indigo Diabetes NV has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
72 of the 72 trials are tagged with Diabetic Ketoacidosis itself; the rest are tagged with a narrower condition beneath it.
When did Diabetic Ketoacidosis trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 9 |
| 2024 | 4 |
| 2023 | 6 |
| 2022 | 10 |
| 2021 | 6 |
| 2020 | 4 |
| 2019 | 2 |
| 2018 | 4 |
| 2017 | 4 |
Showing 10 of 22 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 6 trials starting in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Diabetic Ketoacidosis trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 7 |
| Not applicable | 27 |
| Observational | 29 |
How many Diabetic Ketoacidosis trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 9 |
| Active, not recruiting | 2 |
| Completed | 39 |
| Terminated | 7 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Diabetic Ketoacidosis trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Indigo Diabetes NV | 2 |
| Ankara Etlik City Hospital | 1 |
Which drugs are being tested for Diabetic Ketoacidosis? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| BMS-512148 | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Glargine Insulin | 6 |
| NaCl 0.9% NS | 3 |
| IV insulin infusion | 2 |
| Ringer Lactate | 2 |
| insulin infusion with basal insulin | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Diabetic Ketoacidosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Brain oedema | 19 | 1 |
| Major adverse kidney event within 30 days of ED presentation | 6 | 1 |
| Severe Hypoglycemia | 3 | 1 |
| Acidosis | 2 | 1 |
| Intensive Care Unit Admission | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Diabetic Ketoacidosis? (224)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The contribution of end-tidal carbon dioxide monitoring to the management of pediatric patients with diabetic ketoacidosis. | The American journal of emergency medicine | 2026 | Yes |
| Prevention of diabetic ketoacidosis in relatives screened for islet autoantibodies and followed up in the TrialNet Pathway to Prevention study at a single institution in Italy. | Diabetologia | 2025 | Yes |
| Update on Measuring Ketones. | Journal of diabetes science and technology | 2024 | Yes |
| Real-World Use of Control-IQ Technology Is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis Than Historical Data: Results of the Control-IQ Observational (CLIO) Prospective Study. | Diabetes technology & therapeutics | 2024 | Yes |
| Diabetic Ketoacidosis at Diagnosis in Youth with Type 1 Diabetes Is Associated with a Higher Hemoglobin A1c Even with Intensive Insulin Management. | Diabetes technology & therapeutics | 2024 | Yes |
Showing 5 of 224 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.